medigraphic.com
ISSN 1726-6718 (Electronic)
Revista Cubana de Anestesiología y Reanimación

2012, Number 1

<< Back

Revista Cubana de Anestesiología y Reanimación 2012; 11 (1)

Acute pain or episodical due to cancer

Yera NJL

Language: Spanish
References: 25
Page:
PDF size: 137.12 Kb.


ABSTRACT

Introduction: From the concept introduced by the International Association for the Study and Treatment of Pain, the terms acute, subacute, chronic and intermittent pain are considered and key in the course of pain in a cancer patient, as well as the elements related to pain pathophysiology. Objectives: To identify the incidence and prevalence of episodical pain know as "breakthrough pain", the definitions of other authors, the clinical features and its control using opioids.
Development: It is refer to the pathophysiological features of cancer pain and the causes that could originate it in its interrelation with acute pain due to cancer. It is emphasized the role played by the osteoclastic and osteoblastic activity and the allogenic substances produced from the tumor stroma causing the incidental pain. Authors analyzed the definitions of "breakthrough pain" mentioned by some authors. The use of opioids in the basal control of cancer pain and the usefulness of the new opioids of fast action are examined are the ideal treatment of episodical pain due to cancer how we define in Spanish language to the term used in English language during years. Conclusions: It is essential and important the appropriate use of the fentanyl formulas with a good titration of dose to be use.


REFERENCES

  1. Australian and New Zealand College of Anesthetists and Faculty of Pain Medicine. Physiology and Psychology of Acute Pain. In: Acute pain management: scientific evidence. National Health and Medical Research Council, 2005.

  2. Spacek A. Modern concepts of acute and chronic pain management. Biomedicine & Pharmacotherapy 60 (2006) 329_335

  3. Whizar-Lugo VM y Ochoa-Ortíz G. Conceptos Actuales en Dolor por Cáncer. Anestesia en México 2005; 17 (1): 53-69

  4. Plantea GE and Van Itallie TB. Opioids for cancer pain: the challenge of optimizing treatment. Metabolism Clinical and Experimental 2010; 59 (Suppl 1): S47-S52

  5. Alexopoulos EC, Koutsogiannou P, Moratis E, Mestousi A, Jelastopulu E. Pain in cancer patients: The Greek experience. European Journal of Oncology Nursing xxx (2010) 1-5 doi:10.1016/j.ejon.2010.10.008

  6. Mercadante S and Vitrano V. Pain in patients with lung cancer: pathophysiology and treatment. Lung Cancer 2010; 68: 10_15

  7. Saxena A Kr, Kumar S. Management Strategies for Pain in Breast Carcinoma Patients: Current Opinions and Future Perspectives. Pain Practice 2007; 7(2): 163_177

  8. Reyes-Chiquete D. Dolor agudo en el paciente con cáncer. Rev Mexicana de Anestesiología 2005; 28 (1): 175-76

  9. Twycross RG, Fairfield S. Pain in far-advanced cancer. Pain 1982; 14: 303-310.

  10. Svendsen K, Andersen S, Arnason S, Arn S et al. European Journal of Pain 2005; 9: 195-206

  11. Green CR, Montague L, and Hart-Johnson TA. Consistent and breakthrough pain in diverse advanced cancer patients: A longitudinal examination. Journal of Pain and Symptom Management 2009; 37 (5): 831-847

  12. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69 (1-2):1-18.

  13. Rades D, Schild SE and Abraham JL. Treatment of Painful Bone Metastases. Nat Rev Clin Oncol 2010; 7(4) Nature Publishing Group. Medscape Anesthesiology Education

  14. Sabino MAC, and Mantyh PW, Pathophysiology of Bone Cancer Pain. J Support Oncol 2005; 3: 15-24

  15. Mantyh P. The science behind metastatic bone pain. EJC Supplements 2006; 4: 4-8

  16. Portenoy RK, Burton AW, Gabrail N and Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151: 617-624

  17. Mercadante S, Villari P, Ferrera P, Bianchi M et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. Journal of Pain and Symptom Management 2004; 27 (4): 352-359

  18. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain 2009; 13: 331-338

  19. Nabal M y Madrid F. Dolor episódico: definición, etiología y epidemiología. Rev Soc Esp Dolor 2001; 9 (2): 88-93

  20. Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, et al. Assessment and classification of cancer breakthrough pain: A systematic literature review. Pain 2010; 149: 476_482

  21. Zeppetella G. Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief. Journal of Pain and Symptom Management 2008; 35 (5): 563-567

  22. Portenoy RK, Bennett DS, Rauck R, Simon, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006; 7 (8): 583-91

  23. Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S and Mangione S. Intravenous Morphine for Breakthrough (Episodic) Pain in an Acute Palliative Care Unit: A Confirmatory Study. Journal of Pain and Symptom Management 2008; 35:(3): 307-313

  24. Looi YC and Audisio RA. A review of the literature on post-operative pain in older cancer patients. European Journal of Cancer 2007; 43: 2222 - 2230

  25. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing Crit Rev Oncol/Hematol (2011), doi: 10.1016/ j.critrevonc. 2010.12.002




2020     |     www.medigraphic.com